Gulf Pharmaceutical Industries (JULPHAR) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Gulf Pharmaceutical Industries

Why is Gulf Pharmaceutical Industries ?

With a growth in Net Sales of 12.96%, the company declared Very Positive results in Jun 25

The company has declared positive results for the last 4 consecutive quarters
OPERATING CASH FLOW(Y) Highest at AED 145.7 MM
ROCE(HY) Highest at 6.2%
INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost

With ROE of 2.04%, it has a expensive valuation with a 2.00 Price to Book Value

Over the past year, while the stock has generated a return of -20.75%, its profits have risen by 116.3% ; the PEG ratio of the company is 0.8

Underperformed the market in the last 1 year

Even though the market (Abu Dhabi Securities Exchange) has generated returns of 9.12% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -20.75% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Gulf Pharmaceutical Industries for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Gulf Pharmaceutical Industries

-100.0%

0.93

48.11%

Abu Dhabi Securities Exchange

7.69%

1.13

8.08%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

24.78%

EBIT Growth (5y)

16.91%

EBIT to Interest (avg)

-2.30

Debt to EBITDA (avg)

73.60

Net Debt to Equity (avg)

0.03

Sales to Capital Employed (avg)

0.86

Tax Ratio

10.72%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

1.26%

ROE (avg)

0.76%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.61

EV to EBIT

22.25

EV to EBITDA

11.29

EV to Capital Employed

1.60

EV to Sales

1.36

PEG Ratio

0.14

Dividend Yield

ROCE (Latest)

7.20%

ROE (Latest)

5.76%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

Bearish

No Signal

Bollinger Bands

Bearish

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

23What is working for the Company

OPERATING CASH FLOW(Y)

Highest at AED 145.7 MM

ROCE(HY)

Highest at 6.2%

INTEREST COVERAGE RATIO(Q)

The company hardly has any interest cost

RAW MATERIAL COST(Y)

Fallen by -29.28% (YoY

CASH AND EQV(HY)

Highest at AED 911 MM

DEBT-EQUITY RATIO (HY)

Lowest at 5.97 %

PRE-TAX PROFIT(Q)

At AED 19.4 MM has Grown at 93.52%

NET PROFIT(Q)

At AED 16.9 MM has Grown at 93.14%

-4What is not working for the Company

NET SALES(9M)

At AED 719.6 MM has Grown at -44.46%

DEBTORS TURNOVER RATIO(HY)

Lowest at 1.68%

Here's what is working for Gulf Pharmaceutical Industries

Operating Cash Flow

Highest at AED 145.7 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (AED MM)

Pre-Tax Profit

At AED 19.4 MM has Grown at 93.52%

over average net sales of the previous four periods of AED 10.03 MM

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (AED MM)

Net Profit

At AED 16.9 MM has Grown at 93.14%

over average net sales of the previous four periods of AED 8.75 MM

MOJO Watch

Near term Net Profit trend is positive

Net Profit (AED MM)

Cash and Eqv

Highest at AED 911 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at 5.97 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -29.28% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Gulf Pharmaceutical Industries

Net Sales

At AED 719.6 MM has Grown at -44.46%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (AED MM)

Debtors Turnover Ratio

Lowest at 1.68%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio